MERIDEN, Conn., Feb. 20, 2013 /PRNewswire/ -- Protein Sciences Corporation announced today that Wayne Hachey , DO (Colonel, U.S. Army, ret.) has joined the Company's management as Head, Government and Clinical Affairs. Dr. Hachey is a physician who has dedicated 28 years of service to the military healthcare system, including six years as a subject matter expert advising senior Department of Defense (DoD) leadership regarding the DoD's vaccine policy. He was also responsible for developing the overarching DoD mitigation response to pandemic influenza and directed the implementation of that policy during the 2009 H1N1 pandemic. Most recently, Dr. Hachey served as the Chief of Public Health for the 1st Medical Brigade in Afghanistan where he provided public health leadership to protect over 98,000 U.S. troops. He is board certified in Public Health, Pediatrics and Neonatal-Perinatal Medicine and has won numerous awards, including the Defense Meritorious Service Medal, Meritorious Service Medal, NATO (Afghanistan) and Afghanistan Campaign Medal and Unit Combat Patch.
Dr. Manon Cox , MBA, President and CEO of Protein Sciences commented, "We are delighted to welcome Dr. Hachey to our team." She added, "In his new role, his primary responsibility will be to play a key role in our Company's interactions with government agencies."
Dr. Hachey will represent Protein Sciences at the following meetings this week where the Company's revolutionary new influenza vaccine Flublok® will be presented:
The Advisory Committee on Immunization Practices (ACIP) Meeting
February 20-21, 2013
CDC, Atlanta, GA
2013 AAAAI Annual Meeting
February 22-26, 2013
San Antonio, TX
Protein Sciences Corporation is a vaccine development and protein production company based in Meriden, CT that is dedicated to saving lives and improving health through the creation of innovative vaccines and biopharmaceuticals. Our proprietary baculovirus expression vector system (BEVS) technology provides a fast, reliable and inexpensive platform for the production of high quality recombinant proteins, making it a powerful tool for producing vaccines and therapeutics when they are needed most. BEVS technology is covered by broad patents that include our proprietary expresSF+® cell line that we use to make all of our products.
On January 16, the FDA approved Flublok, a novel influenza vaccine for the prevention of influenza in adults aged 18-49 years old. The FDA has called Flublok a revolutionary vaccine as no eggs or live influenza virus is used in its manufacturing process. In addition, the product does not contain a preservative (e.g., thimerosal), latex, adjuvants or other additives.
|SOURCE Protein Sciences Corporation|
Copyright©2012 PR Newswire.
All rights reserved